Verve Therapeutics Inc (VERV)
6.66
-0.08
(-1.23%)
USD |
NASDAQ |
Apr 18, 16:00
6.67
+0.01
(+0.15%)
After-Hours: 18:56
Verve Therapeutics Cash from Investing (TTM): 27.69M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 27.69M |
| September 30, 2023 | -131.73M |
| June 30, 2023 | -175.41M |
| March 31, 2023 | -200.66M |
| December 31, 2022 | -155.96M |
| September 30, 2022 | -44.63M |
| June 30, 2022 | -201.43M |
| Date | Value |
|---|---|
| March 31, 2022 | -190.72M |
| December 31, 2021 | -239.10M |
| September 30, 2021 | -170.23M |
| June 30, 2021 | 39.37M |
| March 31, 2021 | -48.05M |
| December 31, 2020 | -51.13M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-239.10M
Minimum
Dec 2021
39.37M
Maximum
Jun 2021
-118.61M
Average
-155.96M
Median
Dec 2022
Cash from Investing (TTM) Benchmarks
| Acorda Therapeutics Inc | -0.264M |
| Eli Lilly and Co | -7.153B |
| Intellia Therapeutics Inc | -31.35M |
| Beam Therapeutics Inc | 71.84M |
| Editas Medicine Inc | -3.731M |